文献速递肝病

当前或既往乙肝感染不增加新冠患者死亡风险

Current and Past Infections of HBV Do Not Increase Mortality in Patients With COVID-19.
PubMed 文献 · Hepatology · 2021-06-21

香港全境回顾性队列纳入5639例新冠患者,当前和既往HBV感染分别占6.3%和6.4%。中位随访14天,急性肝损伤而非当前或既往HBV感染与死亡相关(aHR 2.45),HBV感染状态与急性肝损伤及死亡均无显著关联。

要点

  • 当前或既往HBV感染不增加新冠患者急性肝损伤风险
  • 当前或既往HBV感染不增加新冠患者死亡风险
  • 急性肝损伤本身与新冠患者死亡风险升高相关

核心结论

  • 当前或既往HBV感染与新冠患者肝损伤及死亡风险无显著关联。

研究设计与样本

  • 香港全境回顾性队列研究,纳入2020年1月23日至2021年1月1日新冠患者,排除丙肝或无HBsAg结果者,共5639例。

主要发现

  • 当前HBV感染353例(6.3%),既往HBV感染359例(6.4%);中位随访14(9-20)天,138例(2.4%)死亡。
  • 无、当前、既往HBV感染患者急性肝损伤分别发生58例(1.2%)、8例(2.3%)、11例(3.1%)。
  • 急性肝损伤与死亡相关(aHR 2.45;95%CI 1.52-3.96;P<0.001),当前HBV感染(aHR 1.29;95%CI 0.61-2.70;P=0.507)和既往HBV感染(aHR 0.90;95%CI 0.56-1.46;P=0.681)与死亡无显著关联。
  • 使用皮质类固醇、抗真菌药、利巴韦林或洛匹那韦-利托那韦与急性肝损伤相关(aOR 2.55-5.63),当前HBV感染(aOR 1.93;95%CI 0.88-4.24;P=0.102)和既往HBV感染(aOR 1.25;95%CI 0.62-2.55;P=0.533)与急性肝损伤无显著关联。

关键数值与推荐

  • 急性肝损伤定义为ALT或AST≥2倍正常上限(ULN,即80 U/L),且总胆红素≥2倍ULN(即2.2 mg/dL)和/或INR≥1.7。

临床怎么用

  • 新冠患者合并当前或既往HBV感染时,无需因HBV感染状态而额外担忧死亡或肝损伤风险升高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: We compared risk of acute liver injury and mortality in patients with COVID-19 and current, past, and no HBV infection. APPROACH AND RESULTS: This was a territory-wide retrospective cohort study in Hong Kong. Patients with COVID-19 between January 23, 2020, and January 1, 2021, were identified. Patients with hepatitis C or no HBsAg results were excluded. The primary outcome was mortality. Acute liver injury was defined as alanine aminotransferase or aspartate aminotransferase ≥2 × upper limit of normal (ULN; i.e., 80 U/L), with total bilirubin ≥2 × ULN (i.e., 2.2 mg/dL) and/or international normalized ratio ≥1.7. Of 5,639 patients included, 353 (6.3%) and 359 (6.4%) had current and past HBV infection, respectively. Compared to patients without known HBV exposure, current HBV-infected patients were older and more likely to have cirrhosis. Past HBV-infected patients were the oldest, and more had diabetes and cardiovascular disease. At a median follow-up of 14 (9-20) days, 138 (2.4%) patients died; acute liver injury occurred in 58 (1.2%), 8 (2.3%), and 11 (3.1%) patients with no, current, and past HBV infection, respectively. Acute liver injury (adjusted HR [aHR], 2.45; 95% CI, 1.52-3.96; P < 0.001), but not current (aHR, 1.29; 95% CI, 0.61-2.70; P = 0.507) or past (aHR, 0.90; 95% CI, 0.56-1.46; P = 0.681) HBV infection, was associated with mortality. Use of corticosteroid, antifungal, ribavirin, or lopinavir-ritonavir (adjusted OR [aOR], 2.55-5.63), but not current (aOR, 1.93; 95% CI, 0.88-4.24; P = 0.102) or past (aOR, 1.25; 95% CI, 0.62-2.55; P = 0.533) HBV infection, was associated with acute liver injury. CONCLUSION: Current or past HBV infections were not associated with more liver injury and mortality in COVID-19.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Yip TC, Wong VW, Lui GC, et al. Current and Past Infections of HBV Do Not Increase Mortality in Patients With COVID-19. Hepatology. 2021. PMID: 33961298. doi:10.1002/hep.31890

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。